BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 29891694)

  • 1. Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma.
    Priolo C; Khabibullin D; Reznik E; Filippakis H; Ogórek B; Kavanagh TR; Nijmeh J; Herbert ZT; Asara JM; Kwiatkowski DJ; Wu CL; Henske EP
    Proc Natl Acad Sci U S A; 2018 Jul; 115(27):E6274-E6282. PubMed ID: 29891694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
    Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
    Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11.
    Zhang L; Hobeika CS; Khabibullin D; Yu D; Filippakis H; Alchoueiry M; Tang Y; Lam HC; Tsvetkov P; Georgiou G; Lamb C; Stone E; Puigserver P; Priolo C; Henske EP
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2122840119. PubMed ID: 35867762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
    Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
    Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.
    Ruiz-Cordero R; Rao P; Li L; Qi Y; Atherton D; Peng B; Singh RR; Kim TB; Kawakami F; Routbort MJ; Alouch N; Chow CB; Tang X; Lu W; Brimo F; Matin SF; Wood CG; Tannir NM; Wistuba II; Chen K; Wang J; Medeiros LJ; Karam JA; Tamboli P; Sircar K
    Mod Pathol; 2019 Nov; 32(11):1698-1707. PubMed ID: 31231128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression.
    Bansal A; Sanchez DJ; Nimgaonkar V; Sanchez D; Riscal R; Skuli N; Simon MC
    Mol Cancer Res; 2019 Sep; 17(9):1881-1892. PubMed ID: 31151999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Exosomal Gamma-Glutamyltransferase Activity Increased in Patients with Renal Cell Carcinoma with Advanced Clinicopathological Features.
    Horie K; Kawakami K; Fujita Y; Matsuda Y; Arai T; Suzui N; Miyazaki T; Koie T; Mizutani K; Ito M
    Oncology; 2020; 98(10):734-742. PubMed ID: 32726790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromophobe renal cell carcinoma: New genetic and metabolic insights.
    Zhang L; Henske EP
    Urol Oncol; 2020 Aug; 38(8):678-681. PubMed ID: 32444178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromophobe renal cell carcinoma.
    Henske EP; Cheng L; Hakimi AA; Choueiri TK; Braun DA
    Cancer Cell; 2023 Aug; 41(8):1383-1388. PubMed ID: 37541245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
    Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
    Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?
    Ng KL; Del Vecchio SJ; Samaratunga H; Morais C; Rajandram R; Vesey DA; Wood ST; Gobe GC
    Pathology; 2018 Aug; 50(5):504-510. PubMed ID: 29970253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms.
    Petit A; Castillo M; Santos M; Mellado B; Alcover JB; Mallofré C
    Am J Surg Pathol; 2004 May; 28(5):676-8. PubMed ID: 15105658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case.
    Pires-Luis A; Montezuma D; Vieira J; Ramalho-Carvalho J; Santos C; Teixeira M; Jerónimo C; Henrique R
    Exp Mol Pathol; 2018 Dec; 105(3):352-356. PubMed ID: 30343009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma.
    Blanco L; Larrinaga G; Pérez I; López JI; Gil J; Agirregoitia E; Varona A
    Am J Physiol Renal Physiol; 2008 Apr; 294(4):F850-8. PubMed ID: 18216146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients-A Tale of Two Cities: Sequencing Analysis Reveals Dual Lineage Markers Capturing the 2 Cellular Populations of HOT.
    Wang XM; Mannan R; Zhang Y; Chinnaiyan A; Rangaswamy R; Chugh S; Su F; Cao X; Wang R; Skala SL; Hafez KS; Vaishampayan U; Mckenney J; Picken MM; Gupta S; Alaghehbandan R; Tretiakova M; Argani P; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Am J Surg Pathol; 2024 Feb; 48(2):163-173. PubMed ID: 37994665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive review of chromophobe renal cell carcinoma.
    Garje R; Elhag D; Yasin HA; Acharya L; Vaena D; Dahmoush L
    Crit Rev Oncol Hematol; 2021 Apr; 160():103287. PubMed ID: 33753250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.